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Round Table Discussion
Antiretroviral therapy is only part of it
Anthony Mbewu1
There is as yet no cure for AIDS, but therapeutic
strategies must play a part in any comprehensive
approach to the epidemic — even in resource-poor
countries. Farmer et al. (1) provide a starting point,
but manymore clinical trials are needed to investigate
the efficacy of antiretrovirals (ARVs) in prolonging
life and improving the quality of life lived with AIDS
in developing countries (2).
This is because AIDS treatment in developing
countries involves more than simply using western
therapies in tropical settings (3). ARVs neither
eradicate the virus from the body nor cure the
disease. Also, potentially more effective new treat-
ments are being developed in countries of the South
or in collaboration with the North, including
immunomodulatory agents isolated from traditional
medicines, holistic approaches to AIDS care, and
fusion inhibitors. Lastly, intersectoral approaches are
vital to improve access to drugs, such as the recent
successful court action of the South African govern-
ment against the pharmaceutical industry.
Lack of monitoring facilities forced Farmer et
al. to adopt treatment algorithms that may actually be
themost appropriate— i.e. treatment late rather than
early in the course of the disease, as recently
recommended by the expert committee convened
by the US National Institutes of Health. This could
cut costs by reducing the numbers for whom
treatment is indicated. Nevertheless initial diagnosis
should include a CD4 count, as accurate diagnosis
and appropriate selection of patients for treatment is
crucial. Treatment of newly infected patients requires
more research.
Piggybacking highly active antiretroviral ther-
apy (HAART) on the standard directly observed
treatment short course for tuberculosis (DOTS)
seems logical because both conditions require a
multidrug regimen; direct observation may be
necessary for the effective use of HAART, for which
default from treatment can be as high as 60%; and
pulmonary TB is the commonest severe AIDS-
related condition in African countries. However, this
approach loses credibility when one considers that
DOTS is curative whereas HAART is not; compli-
ance is much higher for DOTS than for HAART;
DOTS is a six-month regimen, whereas HAART is
lifelong; mortality during DOTS is low whereas
annual mortality of patients on HAART can be 5–
10%; and even with the drastic reductions in price of
ARVs, to US$ 350 per annum, they remain un-
affordable for most developing countries. Even in an
‘‘upper middle’’ income country such as South
Africa, per capita health care expenditure in the
public sector is only US$ 88 per annum.
Further pilot studies of ARV therapy in the
public sector in developing countries (such as the
‘Protest initiative’ of WHO) are needed and, as
Farmer et al. show, must be comprehensive,
incorporating counselling, fixed dose combinations,
structured treatment interruption protocols, preven-
tion strategies, behavioural research, multivitamins,
nutrition, treatment for opportunistic infections,
therapy for sexually transmitted diseases, sexual
health education, psychological support, poverty
alleviation, social welfare support, and provision of
clean water and sanitation as well as housing. n
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HAART — the need for strategically
focused investments
Richard Feachem1
Farmer and his colleagues stress the importance of
both prevention and treatment of HIV, in the light of
an unparallelled global catastrophe (1). I fully agree.
Their paper also describes some of the good progress
made in Haiti through the work of their team. I am
impressed by this work. The paper calls for
antiretroviral drugs to be made available at a greatly
reduced cost (as indeed is occurring). Again, I am in
full agreement.
My dilemma is that the world is still a long way
from being able to make antiretroviral drugs, even if
they were free, effectively available to the majority of
the people who are infected with HIV. I wish that the
world was different. I wish that poor countries were
not so poor. I wish that the health systems of poor
countries were not so dysfunctional. I wish that rich
countries were far more generous in their support for
health sector activities in poor countries. Regrettably,
none of this is the case in the real world in which we
live. Farmer and his colleagues do not give us a clear
idea of how to overcome these major constraints.
Let me caricature the debate on highly active
antiretroviral therapy (HAART). On one side is the
opinion: ‘‘HAART is too difficult, too expensive, and
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too prone to divert resources from other priority
health investments, fuel drug resistance, and under-
mine progress in behavioural change. We should not
launch into this on a large scale.’’ On the other side is
the position: ‘‘HAART is a human right. Therapy that
is available to gay men in San Francisco and Sydney
should also be available to all infected people
everywhere. We have no choice and no alternative.
We must act on a huge scale and we must do so
immediately.’’
The first position, it seems to me, is clearly
wrong, from both a public health and an ethical
perspective. The second position may be right in a
moral sense, but it is not practical. To advocate the
impossible is to put at risk the achievement of more
limited objectives.
The key to the achievement of more limited
objectives is geographical focus. The experience of
health development work is full of examples in which
international agencies, with the best intentions, have
tried to do too many things in too many places and
have, as a result, achieved little. Being spread too thin
is as undesirable in health investment as in any other
form of human endeavour.What is needed is selected
areas (these could be districts, or small countries, or
towns and their rural hinterlands) in which the
appropriate drugs and delivery systems are put in
place on a serious scale and with adequate levels of
investment. This investment should include the
funding of the necessary research and evaluation
efforts, so that epidemiological and clinical data can
be collected and the programmes can be modified
and improved over time.
These sites would achieve three things. First,
they would bring HAART to tens of thousands of
infected people in an effective way. Second, they
would be islands of good practice where new drugs
and new delivery techniques are continually being
applied and evaluated and a major learning experi-
ence is going on. Third, they would provide powerful
demonstration sites where the cost, impact and
feasibility of using HAART in resource-poor settings
could be clearly seen.
This is not to argue that HAART should be
unavailable in other places in other ways. But it is to
argue that an international effort focused on
establishing and sustaining a number of islands of
learning and good practice is likely to make a greater
contribution to the reduction of suffering and
unnecessary death than spreading limited resources
thinly across the low-income countries.
The approach that I recommend is very
difficult for international agencies to adopt, for
obvious political reasons. It is, however, an approach
that the major foundations can take. The investment
by the Bill and Melinda Gates Foundation in HIV/
AIDS therapy in Botswana is a case in point. Let us
make sure that the best is not seen as the enemy of the
good and that we do not, by calling for unachievable
objectives, undermine the prospects of making good
progress and bringing substantial rewards in the
longer term. n
1. Farmer P et al. Community-based treatment of advanced HIV
disease: introducing DOT-HAART. Bulletin of the World Health
Organization, 2001, 79: 1145–1151.
AIDS care is learnt by doing it
Ariel Pablos-Mendez1
There is consensus that prevention is the most
important strategy to halt the AIDS pandemic (1),
and introducing an HIV vaccine is our ultimate tool
for doing this. However, the inconsistent success of
prevention programmes, and the absence of effective
vaccines now and in any near future, provide ample
grounds for looking more seriously at care for AIDS
patients in resource-poor countries. We have reached
a point of no return, moving from the if and the when
of effective care to the how.
Reasons for taking up the challenge of care now
include the following. First, the sheer magnitude of
the global AIDS crisis. Silently infected before,
millions of people living with HIV/AIDS are now
falling sick and dying. Second, there is moral outrage
over this tragedy when therapy exists for those who
can afford it. Public opinion now demands a shift
from unmitigated suffering to hope. Third, indiffer-
ence to such suffering reduces the credibility of
prevention efforts. Treatment is thus an essential
component of the AIDS control continuum. Fourth,
a 97% reduction in antiretroviral (ARV) prices (2) and
hospital cost savings in Brazil have made previous
arguments over affordability obsolete, and given rise
to confidence that AIDS care in poor countries is not
only feasible but inevitable. Fifth, mounting pressure
— politically and even legally — on multinational
pharmaceutical companies, local governments, and
the international community is opening the door to
new resources.
Universal access to highly active antiretroviral
therapy (HAART) for millions of people is not
feasible today, but doing nothing is unacceptable.
One parallel with tuberculosis (TB) is that a much
simpler and curative regimen reaches only 25% of
patients despite a decade-long campaign (3). AIDS
care is daunting by comparison. Talking of billions of
dollars is easy compared with the demands of setting
priorities (e.g. what regimen, where to start) and
raising and allocating vast resources. But if the risks
are high, so too are the opportunities.
Moving forward, there are at least two steps we
need to take before going full speed ahead:
demonstration projects, and targeted research. Small
pilot projects by dedicated physicians, such as the
Partners in Health work in Haiti (4), bring hope and
suggest the feasibility of AIDS care in poor countries.
Newer models designed to target a specific subset of
1 The Rockefeller Foundation, 420 Fifth Avenue, New York, NY 10018,
USA (email: apablos-mendez@rockfound.org).
Ref. No. 01-1610
1153Bulletin of the World Health Organization, 2001, 79 (12)
Round Table Discussion
the population (e.g. HIV-infected pregnant women)
are another way to advance public health without
overburdening fragile health care systems. Their
experience will show the way forward to the scale-up
of AIDS care in the coming years.
Farmer et al. draw on the lessons and
infrastructure of the directly observed treatment
short course for TB (DOTS) to plan for AIDS care
(4). TB programmes, however, cannot be taken for
granted, nor did they evolve overnight (5–7). The
DOTS strategy, for example, calls for passive case
finding, targeting smear-positive cases, and super-
vised outpatient treatment. These controversial
parameters were set through clinical epidemiology
and operational research, enlightened leadership and
management, and unrelenting advocacy and training.
We are not there yet in AIDS care, though we are not
short of ideas to test.
Until recently, AIDS care research in Africa
and its rationale had been neglected (8). Most non-
experts had assumed that we knewhow to treat AIDS
fromwhat had been done in theOECDcountries (9).
In fact, we are today with AIDS treatment where we
were in 1970 with anti-tuberculosis treatment: there
were many drugs developed a decade earlier, which
were life-saving in the hands of experts. It took over
two decades of sound research to develop a
standardized TB programme (DOTS) that could be
implemented in developing countries (later it was
adopted in OECD countries too (10)). Africa cannot
afford to wait two decades to tackle AIDS. Yet, the
required research has been scant, owing to reserva-
tions about the feasibility of HAART, clinical
overconfidence and ethical paralysis.
Scientific research must be marshalled to ‘‘fast
track’’ the scaling-up of AIDS care beyond pilot
projects. Research can bridge the gap between
increasingly cheaper ARVs and the limited infra-
structure to deliver them inAfrica. Research need not
hold back care. We should learn by doing. Better
action can be informed by research, just as research
priorities should be driven by the imperatives of
action. Competing needs in the fight against AIDS
and poverty demand that we go into comprehensive
care armed with the right weapons. The seeds are
sown. n
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HAART in Haiti — evidence needed
Charles Gilks,1 Carla AbouZahr,2
& Tomris Tu¨rmen3
Farmer et al. present a remarkable achievement: the
establishment of a care service for people with HIV/
AIDS in a community of poor displaced people living
in a remote rural area of Haiti (1). The conditions
under which this has been accomplished are
particularly difficult, yet the service has included the
provision of antiretroviral therapy (ART) to 60–
100 people. This has been possible, they argue, by
learning from the history of tuberculosis control and
using a model they have called DOT-HAART
(directly observed therapy with highly active anti-
retroviral therapy), implemented through a team of
community-health workers called ‘‘accompagna-
teurs’’ to supervise therapy.
If the claims of the authors are substantiated,
such a model would have enormous potential for
replication in other resource-poor settings. If, on the
other hand, the authors’ claims are exaggerated, the
potential for doing more harm than good would be
great (and the authors dismissal of the ‘‘spectre of
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acquired drug resistance’’ is alarming). In the end, the
scientific soundness of the evidence must be the
decisive factor. It is unfortunate, therefore, that the
paper reads more like a statement of positive self-
evaluation than a careful presentation and analysis of
the facts. The paper is instructive not so much for
what it presents as for what it does not reveal. It
makes no serious attempt to consider what really are
the lessons for Haiti, and other countries, if they want
to scale up efforts to provide care to those infected
with HIV/AIDS.
The authors’ main contention is that the
concerns voiced about treating HIV-positive people
with HAART — namely high cost of drugs, lack of
health system capacity to deliver them effectively,
possibility of non-compliance, and risk of drug
resistance — are ill-founded. If we are to be
convinced that this is so, we need better evidence
than that provided in this paper. Let us look briefly at
some important issues the authors did not mention.
First, logistics: what clinical input and staff time
was required to set up and then run this intervention?
Apart from the ‘‘accompagnateurs’’, how many
physician hours were involved? In the real world,
any broadly accessible initiative will have to be
clinical-officer or nurse-practitioner led — there just
are not enough physicians to go around. With rapidly
falling prices, capacity, not cost, will be the big issue.
The human resources and capacities needed to
implement the model intervention need to be very
carefully listed for a real evaluation of their
programme to be made.
Second, entry criteria: ad hoc criteria are used to
start individuals on treatment. What are ‘‘recurrent
opportunistic infections difficult to manage with
antibacterials or antifungals’’? What is ‘‘otherwise
unexplained and significant weight loss’’ compared to
‘‘chronic enteropathy with wasting’’? The severe
neurological complications include peripheral neuro-
pathy which may bemore present in the earlier stages
of disease than other problems. The reliance on
haematological indices including low platelet counts
and ‘‘severe leukopaenia’’ (not defined) suggests
access to automated haematology analysers, which
are not available outside research projects or capital
cities. Also, why have patients with active TB been
excluded?
Third, unforseen benefits: what is the evidence
that the intervention has improved staff morale?
What observations have been made for the group to
form an ‘‘impression’’ that AIDS-related stigma has
been reduced? And how do they relate the increase in
voluntary counselling and testing to this intervention
rather than other changes (there is no control group
and many things have changed over the three years)?
We would all want these benefits to be forthcoming,
but public health physicians need evidence rather
than impressions.
Fourth, costs: how much did it cost to deliver
the drugs? Reference is made to 75–80% of the costs
being for medication — but this is for drugs
purchased in which market and at what price? Eighty
per cent of current US prices for triple drug (perhaps
US$ 8000–10 000) is a lot more than 80% of the
current best (cheapest) prices quoted by Me´decins
Sans Frontie`res and other nongovernmental organi-
zations— around US$ 350 per patient per year. This
incomplete presentation of the facts the group may
well have at hand suggests that the costs are high,
which would then put the intervention in a very
different light. Of course any research initiative will
have additional costs which will be shed if other
nongovernmental organizations start to deliver the
model. But if very costly, how can this intervention
ever be scaled up and replicated, and sustained?
By any evaluation criteria — whether cost-
effectiveness, sustainability, feasibility, or absence of
unintended negative consequences — this success
storymust be classified as non-proven. Yes, we know
with exceptional circumstances, motivation, re-
sources and generous research funding positive
outcomes can be achieved, but replication is some-
thing else entirely. Yes, it is true that with huge inputs
the miracle of ART will produce stunning successes.
And certainly, acting when others have failed to do so
is noble. However, for lack of appropriate design and
scientific evaluation, important lessons that might
have been applied in other settings simply cannot be
drawn from this study. n
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